secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0001193125-22-142093
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead appoints Victoria Vakiener to board as independent director
---------------------------------------------------------------------

- Victoria Vakiener appointed effective May 2, 2022, as independent director.
- She has extensive biotech/commercial experience; former CCO of Epizyme and 20+ years at J&J.
- Granted 17,181 restricted stock units vesting over three years as standard director comp.
- Ms. Vakiener also serves on board of Chimerix, a clinical-stage biopharma company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000119312522142093/0001193125-22-142093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000119312522142093/d342404d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-142093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer